Searchable abstracts of presentations at key conferences in endocrinology

ea0049oc11.3 | Obesity | ECE2017

Interleukin-1 antagonism decreases cortisol levels in obese individuals

Urwyler Sandrine , Schutz Philipp , Ebrahimi Fahim , Donath Marc Y. , Christ-Crain Mirjam

Background: Increased cortisol levels in obesity may contribute to the associated metabolic syndrome. In obesity, the activated innate immune system leads to increased interleukin (IL)-1β, which is known to stimulate the release of adrenocorticotropin hormone (ACTH). We therefore hypothesised that in obesity IL-1 antagonism would result in downregulation of the hypothalamo-pituitary-adrenal (HPA) axis, leading to decreased cortisol levels.Methods: I...

ea0049ep687 | Obesity | ECE2017

Effects of IL-1β on the hypothalamic-pituitary-gonadal axis in men with obesity and metabolic syndrome – A randomized, double-blind, placebo-controlled trial

Ebrahimi Fahim , Schuetz Philipp , Mueller Beat , Urwyler Sandrine A , Donath Marc Y , Christ-Crain Mirjam

Background: Low testosterone levels in men appear to be an independent cardiovascular risk factor closely associated with the metabolic syndrome. Reciprocally, the metabolic syndrome leads to a decrease in testosterone levels, suggesting a bidirectional relationship. It has been hypothesized that increased inflammation is causative for the development of obesity-associated hypogonadism. However, clinical evidence supporting this hypothesis is lacking. The aim of the present st...

ea0081p416 | Pituitary and Neuroendocrinology | ECE2022

Cabergoline monotherapy in acromegaly – a multicenter, retrospective, cohort study of non-irradiated patients using current criteria for disease control

A Urwyler Sandrine , Samperi Irene , Lithgow Kirstie , Mavilakandy Akash , Matheou Mike , Ayuk John , Bradley Karin , Pal Aparna , Reddy Narendra , Karavitaki Niki

Background: Dopamine agonists (DA) are included in the management algorithm of acromegaly. Studies on cabergoline monotherapy report IGF-1 normalisation in between 0% and 100% of the patients during treatment periods ranging between 2.6 and 24 months. However, in many of these studies, previous radiotherapy is a confounding factor. Furthermore, real world data applying the current disease control criteria (normal IGF-1 and GH<1 mg/l) are not available. The aim of this stud...

ea0063gp44 | Metabolic Syndrome and Hypoglycaemia | ECE2019

Effects of anti-inflammatory treatment on fibroblast growth factor-21 in obesity and metabolic syndrome

Ebrahimi Fahim , Urwyler Sandrine , Betz Matthias , Christ Emanuel , Schuetz Philipp , Mueller Beat , Donath Marc , Mirjam Christ-Crain

Background: Fibroblast growth factor-21 (FGF21), which has recently been identified as a central regulator of metabolism, is known to be increased in conditions of obesity, insulin resistance, and fatty liver. Likewise, there is evidence that FGF21 increases with systemic inflammation. The aim of this study was to evaluate whether chronic low-grade inflammation might be the underlying mechanism and whether an anti-inflammatory treatment decreases FGF21 levels in metabolic diso...

ea0063gp133 | Obesity | ECE2019

Effect of IL1-receptor antagonist on renin-angiotensin-aldosterone system and hemodynamics in obese individuals

Urwyler Sandrine , Ebrahimi Fahim , Burkard Thilo , Schuetz Philipp , Poglitsch Marko , Beat Mueller , Donath Marc Y , Christ-Crain Mirjam

Background: Interleukin (IL)-1 antagonism decreases systolic blood pressure in obese individuals. However, the underlying mechanism is unknown. Based on experimental data in animals we hypothesised a blood-pressure lowering effect of IL-1-antagonism via modulation of the renin-angiotensin-aldosterone system (RAAS).Methods: In this post-hoc explorative study, we examined short- (2 days) and long-term effects (4 weeks) of IL-1 antagonism (anakinra/Kineret<...

ea0073aep467 | Pituitary and Neuroendocrinology | ECE2021

The GLP-1 receptor agonist dulaglutide reduces fluid intake in primary polydipsia: A randomised controlled trial

Winzeler Bettina , Sailer Clara , David Coynel , Zanchi Davide , Vogt Deborah , Urwyler Sandrine , Refardt Julie , Christ-Crain Mirjam

BackgroundPrimary polydipsia, characterized by excessive fluid intake, carries the risk of water intoxication and hyponatremia, but treatment options are scarce. Glucagon-like peptide-1 (GLP-1) reduces appetite and food intake. In experimental models, they also play a role in thirst and drinking behavior. The aim of this trial was to investigate whether GLP-1 receptor agonists reduce fluid intake in patients with primary polydipsia.<p class="abstext"...

ea0063oc13.2 | Anterior and Posterior pituitary 2 | ECE2019

Empagliflozin increases sodium-levels in patients with the syndrome of inappropriate antidiuretic hormone secretion – a randomized, double-blind, placebo-controlled trial

Refardt Julie , Imber Cornelia , Sailer Clara O , Jeanloz Nica , Potasso Laura , Kutz Alexander , Widmer Andrea , Urwyler Sandrine , Ebrahimi Fahim , Vogt Deborah R , Winzeler Bettina , Christ-Crain Mirjam

Introduction: The syndrome of inappropriate antidiuretic hormone secretion (SIADH) is the predominant cause of hyponatremia but the available treatment options are unsatisfying and often of little efficiency. The selective sodium-glucose co-transporter 2 inhibitor empagliflozin promotes osmotic diuresis due to glucosuria and might be a novel treatment option for SIADH.Material and methods: From September 2016 through December 2018 we randomly assigned 88...

ea0037gp.01.01 | Adrenal | ECE2015

Low-dose ACTH testing does not predict treatment response to corticosteroids in community-acquired pneumonia

Blum Claudine A , Schuetz Philipp , Nigro Nicole , Winzeler Bettina , Arici Birsen , Refardt Julie , Urwyler Sandrine A , Briel Matthias , Mueller Beat , Christ-Crain Mirjam

Background: It is controversial whether the attenuated increase of circulating cortisol to ACTH stimulation predicts treatment response to corticosteroids in patients with critical illness. We investigated whether ACTH testing predicts treatment response to corticosteroids in patients with community-acquired pneumonia (CAP).Methods: We performed a low dose (1 μg) ACTH test on admission in a prospective randomised, double-blind, placebo-controlled mu...

ea0037ep5 | Adrenal cortex | ECE2015

Influence of glucocorticoids on markers of inflammation in community-acquired pneumonia

Blum Claudine A , Nigro Nicole , Schuetz Philipp , Winzeler Bettina , Arici Birsen , Refardt Julie , Urwyler Sandrine A , Briel Matthias , Mueller Beat , Christ-Crain Mirjam

Background: Glucocorticoids are frequently prescribed in inflammatory diseases. We investigated the influence of prednisone on classical and novel inflammatory markers in community-acquired pneumonia (CAP).Methods: We evaluated levels of C-reactive protein (CRP), procalcitonin, leukocyte and neutrophil count in a prospective randomized, double-blind, placebo-controlled multicenter trial which compared prednisone 50 mg for 7 days to placebo in patients ho...

ea0037ep796 | Pituitary: clinical | ECE2015

Changes in mid-regional pro-atrial natriuretic peptide during thirsting separate patients with diabetes insipidus from those with primary polydipsia

Urwyler Sandrine , Timper Katharina , Fenske Wiebke , Kuhn Felix , Frech Nica , Arici Birsen , Rutishauser Jonas , Kopp Peter , Allolio Bruno , Stettler Christoph , Muller Beat , Katan Mira , Christ-Crain Mirjam

Background: The water deprivation test as the accepted gold standard in the differential diagnosis of polyuria polydipsia syndrome can be associated with a decrease in extracellular fluid volume in patients with diabetes insipidus (DI). We herein evaluated mid-regional pro-atrial natriuretic peptide (MR-proANP) as marker of extracellular body volume in patients with diabetes insipidus compared to primary polydipsia (PP), at baseline and after water deprivation.<p class="ab...